Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Clinical trial NCT05811793 · UNKNOWN
Trial details
- NCT number
- NCT05811793
- Sponsor
- Second Affiliated Hospital of Nanchang University
- Status
- UNKNOWN
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-15
- Primary completion
- 2024-12-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.